What is LiquidGx™?

LiquidGx™ is a non-invasive cancer test, based on a simple blood sample, for selecting relevant solid tumor targeted therapies and it represents an alternative to tissue-based biopsies, for when tumor tissue can be difficult to sample.

With LiquidGx™ testing, the health care professional can easily and better monitor disease progression and track the response to targeted therapy, including the development of additional mutations associated with tumor resistance to therapy. Thus, the physician can properly identify the moment to switch treatment to alternative therapies.

Patients and doctors become partners in the journey to faster, smarter and more efficient personalized medical solutions.

Who should take the test?

LiquidGx™ is recommended for patients with diagnosed cancers that need to understand whether they can be candidates for targeted therapies or not, in cases when sampling the tumor cannot or is difficult to be performed.

With LiquidGx™, health care professionals can early detect cancer-driving variants of genes frequently mutated in solid tumors as well as drug resistant markers.

What are the Clinical Benefits of the test?

Used as an alternative when tissue-based biopsy is not available, through patient-centric and easy-to-understand reports, LiquidGx™ is valuable to clinicians and patients struggling with a cancer diagnosis because it directs the physician to the appropriate targeted treatment.

LiquidGx™ helps physicians make informed therapeutic decisions and, because tumors evolve over time and can acquire drug resistance, the use of liquid biopsy helps oncologists properly monitor the possible selection of resistant mutants under currently applied treatments. LiquidGx™ possesses the ability to quantify copies of circulating tumor DNA (ctDNA) thus enabling the physician to survey both evolutions of primary mutation and acquired secondary mutation in order to properly address a switch in treatment.

In a comprehensive, user-friendly report, LiquidGx™ provides recommendations of targeted therapies with potential clinical benefit and valuable information about drugs that will likely not show any benefit due to the presence of resistant markers. Moreover, for each variant found, the report includes up to 5 relevant clinical trials to consider.

What DNA sample is required to perform the test?

LiquidGx™ testing procedure requires just two 10ml tubes of blood that is easily collected by any qualified health care professional.

Frequently Asked Questions

When should LiquidGx™ test be done?

LiquidGx™ is recommended when tissue biopsy is not feasible or safe. The needed blood sample should be collected post-biopsy, post-surgery and at specified time points during treatment.

What genes are screened and what mutations are detected by LiquidGx™?

LiquidGx™ is an amplicon-based cancer test panel designed to provide sensitive and accurate genomic analysis on genes frequently mutated in cancers, EGFR, ERBB2, KRAS, BRAF, MET, ALK, ROS1, RET, PIK3CA, AKT1, NRAS,HRAS, KIT, MAP2K1, PDGFRA, TP53, and PTEN.

Using Next Generation Sequencing (NGS) based technology, this test detects point mutations and small insertions/deletions for EGFR, ERBB2, KRAS, BRAF, ALK, PIK3CA, AKT1, NRAS, HRAS, KIT, MAP2K1, PDGFRA, TP53, and PTEN. It detects copy number variation for EGFR, ERBB2, and MET.

Additionally, it detects fusions for ALK, ROS1, and RET and Exon14 skipping for MET. The test detects if microsatellite instability (MSI) is present by detecting repeat length at BAT-25, BAT-26, NR-21, NR-24, and NR-27.

How long does it take to get the test results?

LiquidGx™ test results will typically be available up to 21 business days following receipt of the blood sample at the lab.

How does the test work?

Designed for precision treatment and drug resistance monitoring, LiquidGx™ assays over 170 variants in 17 genes frequently mutated in cancer. LiquidGx™ utilizes advanced technology to analyze ctDNA/RNA to accurately detect cancer-driving mutations.

LiquidGx™ qPCR allows for the genotyping of ALK, BRAF, EGFR, and KRAS to either be done individually or together, including genomic alterations associated with resistance to targeted cancer drugs, such as EGFR T790M and C797S.

The LiquidGx™ NGS panel includes micro-satellite instability (MSI) for selection of anti-PD1 therapy.

Subscribe for a test

If you or someone you know might be interested in benefiting of LiquidGx™ science to help you choose the best treatment option, subscribe here and one of our experts will setup a planning for you to gain access to this genetic test. Tell us more about your interest and inquiries by filling in the next contact form and we’ll be in touch shortly.

Get in touch

Schedule for a consultation

The testing process may be complex and it’s essential to have a trusted resource when making decisions. With the help of our partner physicians, you will find out the benefits of the LiquidGx™ test, understand the clinical results and make the right decisions for your future health. Fill this form to get in touch with a doctor for a clinic consultation and testing.

Schedule an appointment